DENTSPLY SIRONA XRAY is well-positioned for growth due to its new digital-implant work flow and continued focus on research ...

Morgan Stanley downgraded Dentsply Sirona (XRA) to Equal Weight from Overweight and slashed its price target to $14 from $21 per share on Tuesday, noting that the dental product maker is facing a ...

As previously reported, Morgan Stanley downgraded Dentsply Sirona (XRAY) to Equal Weight from Overweight with a price target of $14, down from ...

BofA lowered the firm’s price target on Dentsply Sirona (XRAY) to $16 from $19 and keeps a Neutral rating on the shares. The firm is ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Investing.com -- On March 18, 2025, Moody’s Ratings altered the outlook for Dentsply Sirona Inc. to negative from stable, while affirming the company’s Baa2 issuer rating, Baa2 senior ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...